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Virus-like particles (VLPs) play a prominent role in vaccination as safe and
highly versatile alternatives to attenuated or inactivated viruses or subunit vac-
cines. We present here two innovations, VLP-factoryTM and ADDomer©, for
creating VLPs displaying entire proteins or peptide epitopes as antigens, re-
spectively, to enable efficient vaccination. For producing these VLPs, we use
MultiBac, a baculovirus expression vector system (BEVS) that we developed
for producing complex protein biologics in insect cells transfected with an en-
gineered baculovirus. VLPs are protein assemblies that share features with
viruses but are devoid of genetic material, and thus considered safe. VLP-
factoryTM represents a customized MultiBac baculovirus tailored to produce
enveloped VLPs based on the M1 capsid protein of influenza virus. We ap-
ply VLP-factoryTM to create an array of influenza-derived VLPs presenting
functional mutant influenza hemagglutinin (HA) glycoprotein variants. More-
over, we describe MultiBac-based production of ADDomer©, a synthetic self-
assembling adenovirus-derived protein-based VLP platform designed to dis-
play multiple copies of pathogenic epitopes at the same time on one particle
for highly efficient vaccination. © 2021 The Authors.
Basic Protocol 1: VLP-factoryTM baculoviral genome generation
Basic Protocol 2: Influenza VLP array generation using VLP-factoryTM
Basic Protocol 3: Influenza VLP purification
Basic Protocol 4: ADDomer© BioBrick design, expression, and purification
Basic Protocol 5: ADDomer© candidate vaccines against infectious diseases
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INTRODUCTION
Recombinant protein production is an essential prerequisite for cost-efficient and versa-
tile production of complex biologics which can be used as scaffolds to display proteins
and peptides that can represent antigenic epitopes from pathogens including viruses that
cause infectious diseases. Viruses are characterized by a proteinaceous shell encasing
and protecting the viral genetic material that is released and replicated upon infection
of the host cell organism. The immune system of the host typically mounts its defense
against pathogenic surface structures representing antigenic epitopes with the objective
to defeat and clear out the pathogen. Early on, it was recognized that administering such
antigenic epitopes, for example in the form of heat-inactivated viral pathogen species,
can result in protective responses setting the stage for vaccinations-arguably the most
successful intervention in terms of saving human lives to date. An attractive alternative
to administering inactivated or attenuated virus derives from recombinant production of
the proteinaceous shell, or parts of it, resulting in virus- like particles (VLPs). VLPs can
be physically similar or even identical to live virus, but devoid of genetic information and
thus safe, as replication cannot occur. VLPs are used for vaccination against a range of
infectious diseases including influenza and viral infection−based malignancies such as
cervical cancer caused by papilloma virus (Charlton & Lua, 2017; Cox & Hollister, 2000;
Jeong & Seong, 2017; Pouyanfard & Mu¨ller, 2017; Schiller & Lowy, 2006; Temchura
& U¨berla, 2017).
Escherichia coli is by and large the dominating system for recombinant protein expres-
sion in molecular biology; however, complex biologics such as VLPs often cannot be ex-
pressed efficiently in E. coli due a plethora of reasons, including post-translational mod-
ifications or specialized folding machineries not present in E.coli but which eukaryotic
expression systems can afford ( Nettleship et al., 2015; Nettleship, Assenberg, Diprose,
Rahman-Huq, & Owens, 2010; Nie et al., 2009; Nie et al., 2016; Vijayachandran et al.,
2011).
The baculovirus expression vector system (BEVS) has emerged as a particularly pow-
erful technology for the production of complex protein biologics that are authentically
targeted and post-translationally modified including disulfide-bond formation and glyco-
sylation. We developed MultiBac, a modular baculovirus-based expression system par-
ticularly suited for efficiently producing challenging protein assemblies for a wide range
of applications, as we and others have described in considerable detail (e.g., Barford,
Takagi, Schultz, & Berger, 2013; Berger et al., 2013; Berger, Fitzgerald, & Richmond,
2004; Bieniossek, Imasaki, Takagi, & Berger, 2012; Bieniossek, Richmond, & Berger,
2008; Fitzgerald et al., 2006; Fitzgerald et al., 2007; Nie et al., 2009; Sari et al., 2016;
Trowitzsch, Bieniossek, Nie, Garzoni, & Berger, 2010; Trowitzsch, Palmberger, Fitzger-
ald, Takagi, & Berger, 2012; Vijayachandran et al., 2011). MultiBac has been widely
adopted in academia and industry, accelerating research and development world-wide,
with the focus in recent years shifting to customizing the system for specialized tasks
including, for example, humanized glycoprotein production (Palmberger, Klausberger,
Berger, & Grabherr, 2013; Palmberger, Wilson, Berger, Grabherr, & Rendic, 2012),Sari-Ak et al.
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Figure 1 MultiBac-Based VLP-factoryTM. On the right, the MultiBac baculoviral genome cus-
tomized for enveloped virus-like particle production is shown schematically. The capsid-forming
influenza H1N1 matrix protein M1 and the fluorescent protein mCherry are integrated into the viral
backbone. The mCherry protein is a reporter for tracking virus performance. Influenza surface pro-
tein (hemagglutinin HA and/or neuraminidase NA) insertion into this VLP-factoryTM by means of
transfer plasmids results in baculoviruses producing influenza virus-like particles (VLPs). Electron
micrographs of a selection of the VLPs is shown below. Recombinant influenza VLPs produced by
the customized MultiBac genome (VLP-factoryTM) and live influenza virus are close to identical in
terms of size, shape, and appearance (inset, image courtesy of R. Ruigrok). Scale bars (50 μm)
are drawn in white (adapted from Sari-Ak et al., 2019).
genetic code expansion (Koehler et al., 2016), or multifunctional DNA delivery in mam-
malian and human cells and tissues, among others (Aulicino, Capin, & Berger, 2020;
Mansouri et al., 2016; Sari et al., 2016).
In this article, we describe VLP-factoryTM, a customized MultiBac system that is tailored
for high-level expression of VLP based on influenza M1 capsid protein. A gene encoding
M1 from H1N1 influenza strain, as well as a gene encoding mCherry fluorescent protein
for monitoring the course of virus amplification and VLP production in the cell culture,
were integrated into the viral backbone (Fig. 1). An array of influenza VLPs including sets
of mutations in a potentially immune-suppressive domain (ISD) within the influenza sur-
face protein hemagglutinin (HA) were efficiently produced using VLP-factoryTM. ISDs
were discovered in retroviruses, and evidence suggests that influenza HA also comprises
an ISD overlapping with its fusion peptide segment, potentially impacting on innate im-
mune responses in macrophages and dendritic cells (Bahrami, Laska, Pedersen, & Duch,
2016; Holm et al., 2012). The ISD is located on the structurally sensitive part of HA,
which is critical for membrane fusion. Hence, any design in this part that would abolish
immune suppression and enhance antigenicity would need to be carefully crafted to main-
tain HA functionality in membrane fusion. To identify such mutants, an array of influenza
VLPs containing randomized amino acids at certain positions in the ISD were required
(Sari-Ak et al., 2019). Resulting influenza VLP variants (wild-type HA or HA ISD mu-
tants) can be functionally tested for membrane fusion activity in vitro as well as immune-
suppressive activity in vivo in animal models. It would be very useful to have influenza
VLPs containing ISD mutations for use as VLP-based hyper-immunogenic antigens that Sari-Ak et al.
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could represent strongly and broadly protecting influenza vaccines. HA-comprising ISD
mutations identified as most potent in abolishing immune suppression and increasing HA
antigenicity will likely elicit stronger neutralizing antibody titers upon administration as
compared to unmodified HA. The process of preparing M1-based influenza VLPs com-
prising HA with a series of ISD mutations is detailed here. By the same token, other viral
or non-viral glycoproteins, domains thereof, or structured epitopes or target proteins of
choice can be displayed efficiently using VLP-factory, by providing a native or heterol-
ogous transmembrane domain to anchor the proteins to be displayed on the enveloped
VLP surface.
Transfer plasmid generation and insertion into the MultiBac genome are detailed in our
previous publications (Bieniossek et al., 2008; Fitzgerald et al., 2006; Haffke, Viola, Nie,
& Berger, 2013). Therefore, in this article, we focus on the process of production, pu-
rification, and analysis of the influenza VLP array using VLP-factoryTM, our customized
MultiBac-derived baculoviral expression tool. Influenza M1 protein is the key element of
VLP-factoryTM. We identified M1 from the H1N1 influenza strain as particularly suited
for self-assembly and capsid formation (Sari-Ak et al., 2019). Moreover, capsids formed
by H1N1 M1 are readily released from the cells in the expression culture, acquiring the
lipid bilayer envelope comprising heterologously expressed membrane proteins during
the budding process. Because of these characteristics of H1N1 M1, our VLP-factoryTM
is not limited to flu VLPs with HA in the envelope, but can be used to produce VLPs
displaying diverse viral envelope proteins, one or several simultaneously, from diverse
influenza subtypes or even from other pathogens, that are expressed from genes inserted
in addition to M1 and mCherry into the VLP-factoryTM baculovirus. These proteins will
then be successfully integrated in the cell membrane and thus into the envelope of M1-
based VLPs during budding, as shown here for HA. VLP-factoryTM, thus, has consider-
able potential as a flexible production tool for a wide range of VLP vaccines displaying
surface protein antigens of viral pathogens.
Non-enveloped VLPs lacking a lipid membrane likewise represent popular candidates for
new and better vaccines (Bachmann et al., 2013; Draper, et al., 2010; Frietze, Peabody, &
Chackerian, 2016; Fuenmayor, God̀ia, & Cervera, 2017; Unzueta et al., 2015). A major
drawback of enveloped VLPs, but also of many protein-only VLPs currently available,
and in fact of most vaccines currently deployed, originates from their lack of thermosta-
bility, necessitating an elaborate cold-chain from production to point-of-care to maintain
refrigeration, which is often difficult or even impossible in poor and remote areas, leading
to significant losses (Ashok, Brison, & LeTallec, 2016).
To overcome these limitations, we developed ADDomer©, our synthetic self-assembling
multiepitope peptide display scaffold for highly efficient vaccination (Vragniau et al.,
2019) (Fig. 2). ADDomer© is derived from a component of human adenovirus, the so-
called penton base protein. Adenoviruses are widely used in gene therapy and considered
safe (Crystal, 2014). The adenovirus capsid consists of hexons, pentons, and fiber extru-
sions. Intriguingly, the penton-forming base protein of some adenovirus serotypes can
spontaneously self-assemble into a symmetric particle consisting of 60 protomers (Nor-
rby, 1966). These protomers assemble into 12 pentons forming a dodecahedron, pre-
serving adenovirus-like ability to penetrate epithelial cells (Fender, Boussaid, Mezin,
& Chroboczek, 2005). Exploiting these characteristics, we developed ADDomer©, our
thermostable synthetic dodecahedron platform for highly efficient multiepitope display,
as a next-generation VLP platform for vaccines and protein therapeutics (Vragniau et al.,
2019). ADDomer© is produced at high levels using our MultiBac baculovirus expres-
sion system. A wide range of epitopes can be displayed using ADDomer, including, to
date, epitopes as short as a few amino acids or encompassing several hundred amino acid
residues, potentially including structured domains (Vragniau et al., 2019).Sari-Ak et al.
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Figure 2 The ADDomer©. Electron cryo-microscopy (Cryo-EM) map of the synthetic self-
assembling ADDomer© particle, formed by 60 identical protomers. The protomers assemble into
12 pentons, forming a dodecahedron characterized by remarkable thermostability (Vragniau et al.,
2019).
This article presents detailed instructions for generating, by utilizing VLP-factoryTM, an
influenza VLP array displaying mutants of the HA glycoprotein. Moreover, this article
presents the MultiBac-based approach of the Ad3-derived ADDomer© for displaying
multiple peptide epitopes. Basic Protocol 1 provides instructions for VLP-factory bac-
uloviral genome generation. Basic Protocol 2 outlines stages to prepare the influenza
VLP Array by using VLP-factoryTM. Basic Protocol 3 describes purification of influenza
VLPs. The different parts of the project are illustrated in a workflow diagram (Fig. 3). Ba-
sic Protocol 4 details how to design, produce, and purify ADDomer© using the MultiBac
system. Finally, in Basic Protocol 5, the approach to engineer the ADDomer© platform
for vaccine development against an infectious disease is explained.
STRATEGIC PLANNING
It is critical to plan in advance all the procedures in detail to successfully produce VLPs
with the MultiBac baculovirus/insect cell expression system. For gene insertion using
the transfer plasmids of the MultiBac system, we recommend planning all steps of the
cloning process in silico via suitable software at the beginning of all multiprotein complex
expression projects.
Some of the gene expression cassettes are integrated by site-specific recombination us-
ing Cre recombinase. We recommend planning this part carefully beforehand using our
published protocols (Bieniossek et al., 2008; Fitzgerald et al., 2006).
An objective of the influenza VLP array produced by the VLP-factoryTM is to identify
mutants that maintain the HA membrane fusion feature while simultaneously inactivat-
ing the immune suppressive activity, with the aim to induce stronger immune responses
by the resulting VLP vaccine candidates. We describe here the protocol for production
of the influenza VLP variants (wild-type HA or HA ISD mutants). A particular chal-
lenge regarding execution of this protocol resides in the many baculoviruses produced in
parallel for the expression for different ISD mutants, requiring the utmost care to avoid




Figure 3 Overview of VLP-factoryTM protocol. VLP-factoryTM was created for the expression of a
functional influenza VLP variant assay. A transfer plasmid library including genes encoding wild-
type and mutant influenza HA5 and HAB proteins was transformed into VLP-factoryTM (Basic Pro-
tocol 1). Illustrated is the initial virus in 6-well plates, already giving the signal for the expression of
mCherry that we perceive from the red color change (Basic Protocol 2). Parallel expression enables
extraction and purification of the influenza VLPs by sedimentation and gradient centrifugation for
functional studies (Basic Protocol 3).
BASIC
PROTOCOL 1
VLP-FACTORYTM BACULOVIRAL GENOME GENERATION
The influenza M1 and HA subunits and the functional mutant−encoding genes are de-
signed in silico using a DNA cloning software of choice (i.e., VectorNTI, ApE, others).
and are then inserted into transfer plasmids of choice called Donor and Acceptor (the
MultiBac transfer plasmids available are listed in Table 1 to be used based on the in-
dividual experimental design). In addition to HA, further influenza protein−encoding
genes (NA, M2) can be likewise inserted, resulting in multivalent VLPs. Polycistronic
expression cassettes can be prepared using a variety of different methods-total DNA
synthesis, restriction/ligation cloning, ligation-independent cloning (LIC), sequence and
ligation−independent cloning (SLIC), or Gibson cloning (Casini, Storch, Baldwin, & El-
lis, 2015)-as described in detail previously (Benoit et al., 2016; Celie, Parret, & Perrakis,
2016). The technique used is entirely up to what the individual user feels most com-
fortable with. Given the recent decrease in costs incurred as a result of the competition
among the commercial suppliers, we recommend using custom DNA synthesis (impor-
tantly including complete cassette sequencing also of promoters and terminators), which
will make expression cassette construction easier and faster, in particular for generation
of mutant arrays, as we carried out here for influenza HA.
In this protocol, the plasmid used is created by custom gene synthesis for DNA encoding
M1 from H1N1 influenza virus and hemagglutinin derived from both H1N1 and H5N1
influenza viral strains. We have also used commercial mutagenesis services to insert care-
fully planned potential immune-modulating mutations into the hemagglutinin encoding
genes.
In the in silico design step, it is important to eliminate internal restriction sites, as this
can be important for subcloning into the MultiBac plasmids when we need to insert any
other proteins such as NA and M2, or glycosylases to modulate the sugar structure of theSari-Ak et al.
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Table 1 MultiBac Donor and Acceptor Plasmids

































F1 Tn7L, Tn7R, loxP Kanamycin (50
mg/ml)Ampicillin
(100 mg/ml)
pBADZ-HisCre TOP10 DH10MultiBacCre ColE1 None Zeomycin
(50 mg/ml)(Zeocin)
a
recA- endA- pir- other cloning strains can be used here as well.
b
recA- endA- pir+ other pir gene expressing strains can be used here as well.
heterologous proteins (Palmberger & Rendic, 2015; Palmberger et al., 2012; Palmberger
et al., 2013) for our parallelized expression experiment set-up.
Codon optimization is another key point to be applied for best expression results of
the gene(s) of interest in insect cells, which is done via the web-based algorithms of-
fered by most of the synthetic DNA suppliers (e.g., http://www.idtdna.com/CodonOpt;
or OptimumGeneTM, from http://www.genscript.com), typically free of charge. This pro-
cedure will also eliminate potentially harmful RNA secondary structure elements in the
transcripts.
In this section, MultiBac based VLP-factoryTM production will be described. First, the
preparation of baculoviral genome for the expression of virus-like particles with the genes
inserted into viral backbone encoding M1 from H1N1 influenza strain and mCherry fluo-
rescent protein for monitoring virus performance and VLP production is detailed. Then,
transformation into DH10MultiBac cells comprising the MultiBac baculoviral genome
is described, and finally DH10VLP-factoryTM cells are prepared.
All reagents are prepared using ultrapure water (Millipore Milli-Q system or equivalent;
conductivity of 18.2 M·cm at 25°C) and analytical grade reagents. All the buffers, an-
tibiotics and enzymes are stored at –20°C.
Materials
An empty Donor plasmid (pUCDM is the plasmid used here and for which the
steps below are written) for the insertion of genes encoding influenza H1N1 M1
protein (GenBank ID ABD59883.1) and fluorescent protein mCherry (GenBank
ID ANO45948.1) via multiple cloning sites (Fitzgerald et al., 2006)
Restriction endonucleases and reaction buffers (NEB) Sari-Ak et al.
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T4 DNA ligase and buffer (NEB cat. no. M0202)
E. coli competent cells containing pir gene (for Donor plasmids): e.g., BW23473
or BW23474 strains (Invitrogen)
Agar for pouring plates
Media (LB, TB, SOC; see Current Protocols article: Elbing & Brent, 2018)
Antibiotics (1000× stock): ampicillin (100 mg/ml), kanamycin (50 mg/ml),
chloramphenicol (30 mg/ml), tetracycline (10 mg/ml)
QIAquick plasmid purification kit (Qiagen, cat. no. 27106)
E.coli competent cells DH10MultiBac harboring MultiBac baculoviral genome
(Fitzgerald et al., 2006).
0.1 M CaCl2 (Sigma Aldrich, cat. no. C1016); sterilize by autoclaving
80% (v/v) glycerol (Sigma Aldrich, cat. no. G5516); sterilize by autoclaving
Liquid nitrogen
Cre recombinase enzyme and buffer (NEB cat. no. M0298)
Isopropyl β-D-1-thiogalactopyranoside IPTG (Sigma Aldrich cat. no. I6758).
BluoGal (Sigma Aldrich cat. no. B2904)
Isopropanol
70% ethanol
Insect cell medium (e.g., SF900 II SFM; ThermoFisher) to grow insect cells (cat.
no. 10902088)
Sf21 cells (ECACC 05030202) or Sf9 (ATCC CRL-1711) insect cells growing in
culture
Transfection reagent (e.g., FuGENE from Promega, cat. no. E2311; JetPEI from
Polyplus Transfection, cat. no. 101-10N; or X-tremeGENE from Merck, cat. no.
6366236001)
6-well tissue culture plates; VWR, cat. no. 10062-892
100 × 15 mm petri dishes
Pipettes and pipette tips
Spectrophotometer to determine OD600
Refrigerated centrifuge
42°C water bath or heat block for heat shock
26°C incubator
15-ml Falcon tubes
Additional reagents and equipment for preparing V0 virus (see Current Protocols
article: Biennosek, Richmond, & Berger, 2008, Basic Protocol 5) and agarose
gel electrophoresis (see Current Protocols article: Voytas, 2001)
1. Insert the genes encoding influenza H1N1 M1 protein (GenBank ID ABD59883.1)
and fluorescent protein mCherry (GenBank ID ANO45948.1) into the multiple
cloning sites MCS1 and MCS2 of plasmid pUCDM (Fitzgerald et al., 2006) under
polh and p10 promoter control, respectively, for generating pUCDM-M1-mCherry.
Use generic restriction enzyme/ligation-based cloning or ligation-independent meth-
ods (Casini et al., 2015; Haffke et al., 2013) according to user preference.
2. Transform pUCDM-M1-mCherry into pir+ E.coli cells expressing the pir gene prod-
uct on which propagation of pUCDM-based ‘Donor’ plasmids depend (e.g., PIR1 and
PIR2 from Invitrogen) due to their conditional origin of replication (Fitzgerald et al.,
2006, Metcalf, Jiang, & Wanner, 1994). Plate the transformed cells on LB agar plates
(100 × 15 mm size) containing 30 μg/ml chloramphenicol, and incubate at 37°C
overnight. Use single colonies from this plate to inoculate 25 ml bacterial culture
Luria Broth (LB) medium for growing cells and preparing pUCDM-M1-mCherry




3. Prepare 1 μg of pure pUCDM-M1-mCherry plasmid by using the QIAquick plasmid
purification kit, following the standard plasmid preparation procedure according to
the manufacturer’s instructions.
4. Prepare DH10MultiBacCre chemical competent cells containing the MultiBac bac-
uloviral genome and expressing Cre recombinase enzyme (which catalyzes an in vitro
Cre-LoxP reaction for fusing Donor and Acceptor plasmids via their LoxP sites) ac-
cording to on published procedures (Berger et al., 2004). Briefly:
a. Grow cells in 500 ml sterile LB medium to an OD600 of 0.5-0.6 from an overnight
culture.
b. Centrifuge the cells 10 min at 3000 × g, 4°C. Resuspend and wash twice, each
time with 100 ml of ice-cold 0.1 M CaCl2 at 4°C. Resuspend the final pellet in
5.6 ml of ice cold 0.1 M CaCl2 and 2.4 ml of ice-cold sterile 80% glycerol. Keep
everything at 4°C.
c. Make 100-μl aliquots, flash freeze cells in liquid nitrogen, and finally store at
−80°C.
5. Transform pUCDM-M1-mCherry plasmid into DH10MultiBacCre cells by using a
standard salt-dependent transformation protocol. Briefly:
a. Add 500 ng to 1 μg of the plasmid to the competent cells and incubate on ice for
10-15 min.
b. Subject cells to a heat shock at 42°C for 45-60 s, and then incubate on ice for
2 min.
c. Add 400-500 μl of medium (LB, TB, or SOC) and recover for 4-6 hr or overnight
at 37°C.
d. Plate the cells on LB agar plates containing 10 μg/ml tetracycline, 50 μg/ml
kanamycin, and 30 μg/ml chloramphenicol antibiotics, 1 mM IPTG, and 100 μg/ml
BluOGal color reagent. Incubate at 37°C overnight.
Several blue colonies should grow on the plate.
6. Select a single blue colony for bacterial culture growth by inoculating it in 4-5 ml
of LB medium. Prepare competent cells and store flash-frozen (liquid nitrogen) in
aliquots at −80°C as described in step 4.
These are the DH10 VLP-factoryTM cells containing the MultiBac-based VLP-factory bac-
uloviral genome (Fig. 1).
7. Prepare VLP-factory V0 virus from a frozen aliquot according to published protocol
(see Basic Protocol 5 in Current Protocols article Bieniossek et al., 2008). Briefly:
a. First grow an overnight culture from a frozen cell aliquot from step 6 in 2-3 ml of
LB medium at 37°C shaker.
b. On the next day, spin the cells 10 min at 3000 × g, room temperature. By apply-
ing the QIAquick plasmid purification kit, the pellet is used to prepare bacmid.
Firstly, add 300 μl P1 buffer onto the pellet and pipette the mixture up and down
to resuspend it. Then, transfer the mixture into a new 1.5-ml tube and add 300 μl
P2 buffer. Gently invert the tube until the mixture is homogenous, but do not in-
cubate more than 5 min. Add 300 μl N3 buffer to the tube, and a white precipitate
would appear at this stage. Invert the tube again gently and then spin it 10 min at
17,000 × g, room temperature. Carefully transfer the supernatant into a fresh tube
and spin again for 5 min at 17,000 × g, room temperature.
c. Transfer the supernatant into a fresh tube, add 700 μl of isopropanol, and mix gen-
tly to homogenize. Spin 10 min at 17,000 × g, room temperature. There will be
a small DNA pellet at the bottom; remove the supernatant carefully without dis-
turbing the pellet. Add 200 μl of 70% ethanol to the tube carefully, spin 5 min at Sari-Ak et al.
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17,000 × g, room temperature, and remove the supernatant carefully without dis-
turbing the pellet. Add 50 μl of 70% ethanol and bring the tube into the sterile
hood.
d. Remove the ethanol and let pellet dry. Add 2 ml insect cell medium to 5 wells in a
6-well culture plate and 3 ml insect cell medium to the last well to keep it as a cell
control. Add 0.5-1.0 million Sf21 cells in 1 ml volume to the wells drop by drop,
evenly, except the cell control well, which will only have medium.
Sf21 cells should be used from the batch that have been monitored for 2-3 days before
the infection in terms of showing a healthy profile for cell growth. These cells must be
maintained daily with a fresh insect cell medium to keep the cell density in the flask ideally
in between 0.5 and 1 × 106 cells/ml to ensure optimal growth conditions.
e. Add 30 μl of sterile MilliQ water to the pellet and resuspend the DNA by gently
tapping the bottom of the tube. Transfer 10 μl into a fresh tube to check it on an
agarose gel (see Current Protocols article: Voytas, 2000). Add 200 μl of insect cell
medium to the remaining 20 μl.
f. In a separate fresh tube, add 100 μl of insect cell medium to 10 μl of transfection
reagent and mix, then add 100 of this mix to the tube containing the DNA/medium
mix from step 7e. Mix gently and add 150 μl of the mix drop-by-drop to two wells
of the plate with insect cells. Incubate at 26°C for 48-60 hr without shaking. Cells
that are infected with VLP-factoryTM virus will get bigger in size and will turn




INFLUENZA VLP ARRAY GENERATION USING VLP-FACTORYTM
Here, DH10VLP-factoryTM cells containing baculoviral genome will be transformed
with the transfer plasmid array consisting of wild-type and mutant influenza HA protein-
encoding genes. Hence, we will have the VLP variants expressed in insect cells that we
can visually follow by means of the red color change in the shaker flasks.
Additional Materials (also see Basic Protocol 1)
An empty Acceptor plasmid for the insertion of genes encoding wild type and
mutant influenza HA protein via multiple cloning sites (Fitzgerald et al., 2006)
Erlenmeyer shaker flasks, 250 ml
1. Insert the genes encoding wild-type and mutant influenza HA proteins into the transfer
plasmids (‘Acceptor’, Fitzgerald et al., 2006) as per steps 1-3 of Basic Protocol 1.
These acceptor plasmids contain a common ColE1-derived origin and can be propagated
in any E. coli cloning strains such as TOP10, TG1, DH10, HB101.
2. Transform DH10VLP-factoryTM aliquots with transfer plasmids encoding the ar-
ray made up of wild-type and mutant influenza HA proteins by using standard
a salt-dependent transformation protocol. Next, plate the cells on agar containing
kanamycin, gentamycin, tetracycline, IPTG, and BluOGal.
Refer to Basic Protocol 1, step 5, substeps a-d for the above procedures.
3. Pick a single white colony from each transformation and prepare composite VLP-
factoryTM bacmids. Use these bacmids to infect insect cells in 6-well plates and gen-
erate V0 initial virus.
The bacmid preparation and V0 initial virus production is done as in step 7 of Basic Pro-
tocol 1.
Already at this early V0 stage in 6-well plates, composite VLP-factoryTM produces clones
stained bright red (Fig. 3) from mCherry expression.Sari-Ak et al.
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In case the agar plates are aged (agar plates which were prepared more than a week
ago as a big batch and stored at 4˚C) or there are many colonies on the plate, we
suggest waiting an extra day to observe full blue/white color development, to eliminate
false positive selections.
4. Harvest the VLP-factoryTM V0 viruses producing influenza VLPs after 48-60 hr. Am-
plify to produce V1 virus by adding V0 viruses to 250-ml shaker flasks containing
50 ml insect cell culture (Bieniossek et al., 2008). Cell cultures turn red starting from
24-48 hr post infection. Collect the V1 virus at 24 hr post infection.
We have produced and processed batches of 25 different VLP array members at a time
via this approach, to be able to control logistics. In the high-throughput approaches to
culturing insect cells, parallel processing of many more specimens at the same time in
smaller volumes in a table-top multi-fermenter is possible following established robotics




In this protocol, the purification method is described for the VLPs expressed using VLP-
factoryTM. Once purified as described below, functional assays of choice can be carried
out in vitro and in vivo.
Materials
V1 virus (cell culture from Basic Protocol 2, step 4)
Phosphate-buffered saline (PBS; Thermo Fisher Scientific; cat. no. 10010023)
20% and 60% (w/v) sucrose (Sigma Aldrich; cat. no. S0389) in PBS, autoclaved or
sterile filtered using a 20-μm nylon filter)
Sterile Falcon or Greider tubes (15 ml, 50 ml).
Tabletop centrifuge
Sterile Eppendorf pipettes.
Ultracentrifuge with Beckman SW28 rotor (or equivalent)
38-ml sterile ultracentrifugation tubes (Beckman).
1. Approximately 3 days after proliferation arrest (3 dpa), e.g., when the cell count in
the culture remains unchanged, the cell cultures will have a bright red color due to
co-expressed mCherry (Fig. 3). Transfer the cells into a sterile 50-ml Falcon tube.
2. Spin down cells 3 min at 3000 × g, 4°C, in a tabletop centrifuge. It is important to
process all the influenza VLP purification steps on ice.
Figure 4 Influenza VLPs. A selection of VLP-factoryTM-produced samples were examined by
negative-stain electron microscopy (EM). M1 expression alone already produces budded en-
veloped capsids (top row) in the absence of influenza envelope proteins. Co-expression of in-
fluenza wild-type or mutant HA and HAB results in VLPs displaying the characteristic protruding




Figure 5 VLP-factoryTM-produced influenza VLPs are functionally active. By Western blotting, the
presence of HA protein in HA5 M1 VLP preparation was examined with a specific antibody (H5N1
MIA-0052) showing the presence of specific HA bands (left). The right lane in the Western blot is
the control containing VLPs comprising M1 only, showing no HA signal. M stands for molecular
weight marker (sizes sin kDa). Recombinant influenza VLP was analyzed in a hemolysis experi-
ment (middle). The y axis denotes the percentage of lysed red blood cells (RBC) in the experiment.
The ELISA plot (right) shows antibody titers (IgG1) after two injections (adapted from Sari-Ak et al.,
2019). The y axis represents the level of antibody measured in these experiments.
3. Repeat step 1 with a fresh 50-ml Falcon tube by transferring supernatant to get rid
of cell debris that has been carried over.
4. Ultracentrifuge the cleared supernatant overnight at 121,896 × g, 4°C, in an SW28
rotor or equivalent, with centrifuge tubes containing 38 ml of supernatant each.
5. Resuspend the pellets by gently mixing with a pipette in 1000 μl PBS.
6. Prepare 38-ml volume ultracentrifuge tubes with 20% (w/v) sucrose with a cushion
of around 2 ml of 60% (w/v) sucrose at the bottom of the tube.
7. Load 1 ml of resuspended VLP pellet (from step 4) on top of the 20% sucrose layer.
8. Prepare an identical tube with the same sucrose cushion for use as balance.
9. Ultracentrifuge the tubes overnight at 121,896 × g, 4°C, in an SW28 rotor.
10. Remove 20% sucrose solution by gentle pipetting and collect the white layer be-
tween the two sucrose solutions (interface on top of the 60% cushion).
11. Load the collected white layer on another discontinuous 20%-60% sucrose gradient.
12. Ultracentrifuge the tubes overnight at 121,896 × g, 4°C, in an SW28 rotor.
13. Collect the visible white bands containing purified VLP species and store at 4°C for
further in vitro use, including EM (Fig. 4).
14. To remove sucrose for injection in animal models (Fig. 5) or for other downstream
processing (DSP) procedures such as electron microscopy, ultracentrifuge again as
described above, then carefully remove the sucrose-containing supernatant. Resus-
pend the pellet gently by pipetting up and down in sterile cold PBS (adjust the con-
centration based on the required particle density for injections).
BASIC
PROTOCOL 4
ADDomer© BioBrick DESIGN, EXPRESSION, AND PURIFICATION
The comparison of primary sequences from adenovirus serotypes revealed that two re-
gions in the penton base protein comprise high variability in amino acid sequence and
length. These are the variable loop (VL) and arginine-glycine-aspartic acid (RGD) loop.Sari-Ak et al.
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Figure 6 ADDomer© VLP production. MultiBac-based production of ADDomer©. VLP produc-
tion (Basic Protocol 4) is shown schematically, including a Coomassie-stained SDS-PAGE sec-
tion of highly purified VLP. Plasmid pACEBac-ADDomer comprises the synthetic gene encoding
ADDomer© in a BioBrick format as indicated (adapted from Vragniau et al., 2019). EMBacY is a
version of the MultiBac baculovirus comprising a YFP reporter gene in the viral backbone.VL, inser-
tion site engineered in variable loop; RGD1 and RDG2, insertion sites in RGD loop; Tn7L, Tn7R
and mini-attTn7, recognition and attachment sequences for Tn7 transposase; LoxP, site-specific
recombination site for Cre enzyme; GentR, Gentamicin resistance gene; Kan, Kanamycin; Amp,
Ampicillin; LacZ, gene for blue/white screening of composite genome; oriColE1, replication origin;
YFP, yellow fluorescent protein; M, molecular weight marker (sizes given in kDa).
The RGD loop is characterized by a conserved tripeptide motif (-RGD-) that regulates
integrin-based penetration of the adenovirus into target cells (Gout, Schoehn, Fenel,
Lortat-Jacob, & Fender, 2010).
The low conservation of the VL and RGD loops suggests that one or many antigenic
epitopes can be inserted into these regions of the penton base protein. Starting from the
Ad3 adenovirus serotype, we thus set out to design a synthetic gene in a “BioBrick”
format (Shetty, Endy, & Knight, 2008) providing multiple easily accessible insertion loci
for generating protomers comprising epitope sequences or even small protein domains in
the VL and RGD loops, optionally in a library format (Vragniau et al., 2019). The crystal
structure of the Ad3 protomer (Szolajska et al., 2012) provided guidance for the proper
design of the loci based on the secondary structure motifs flanking the loop regions.
The RGD loop in wild-type Ad3 is significantly larger than the VL, and the RGD mo-
tif is critical for cell internalization. We therefore elected to maintain the RGD motif
and introduce two insertion loci, before and after the RGD tripeptide motif, respectively.
Together with one locus in the VL, we thus engineered our ADDomer© plug-and-play
multiepitope display platform comprising three independent epitope insertion sites.
For high-level expression of ADDomer©, we implemented the MultiBac system (Sari
et al., 2016; Fig. 6), preparing a pACEBac-ADDomer plasmid (Table 1) as a generic
starting point for all epitope insertions exploiting this scaffold (selected examples shown
in Table 2). ADDomer© was expressed with excellent yield (∼1 g ADDomer from 1 liter
of insect cell culture). Quality control of the MultiBac-produced ADDomer© sample










STKDNFNVYKATRPYLAH(Kam et al., 2012) Human infectious disease
Zika DAHAKRQTVVVLGSQEGAV(Shawan et al.,
2014)
OVA SIINFEKL(Villegas-Mendez et al., 2010) Human melanoma model













AAEVKK(Zubieta, Schoehn, Chroboczek, &
Cusack, 2005)
For testing (the combined
RGD loop sequences from
human Adenovirus




The given amino acids in the table above include the epitope flanked by linker residues GGSG (N-term) and GSGG
(C-term) for overall flexibility.
b
Chikungunya epitope consists of an N-terminal linker residue GGSG, and a TEV protease cleavage site right before the
epitope (GGSGENLYFQ’S…, and the TEV recognition site underlined, S as the first serine in epitope sequence).
Materials
Human Ad3 gene sequence encoding the penton base protein (GenBank Z29487)
Plasmid pACEBac1 (Geneva Biotech SARL, Switzerland; see Table 1)
DH10EMBacY cells (Geneva Biotech SARL, Switzerland)
BamHI and HindIII restriction enzymes
Hi5 insect cells (ECACC 94-20-1) growing in culture
SF900 II SFM (Thermo Fisher) to grow insect cells (cat. no. 10902088)
Bovine serum albumin (BSA; New England Biolabs, cat. no. B9200)
Dimethylsulfoxide (DMSO)
Liquid nitrogen
Hypotonic lysis buffer (see recipe)
Phosphate-buffered saline (PBS) solution (Thermo Fisher Scientific, cat. no.
10010023)
15% and 40% (w/v) sucrose
Purification buffer gradient solutions (see recipe)
In silico design software (ApE, SnapGene, Vector NTI)
Centrifuge
Gradient Master 107 (BioComp Instruments)
Ultracentrifuge with Beckman SW28 rotor
Sterile ultracentrifugation tubes (Beckman)
6-8 kDa MWCO dialysis membrane (SpectrumTM Spectra/PorTM; cat. no. 132660)
High Q column (Bio-Rad; cat. no. 7324122)
Additional reagents and equipment for Tn7-dependent integration into baculoviral
genome (see Current Protocols article Bieniossek et al., 2012, Basic Protocol 4),




(Basic Protocol 2, step 4), SDS-PAGE (see Current Protocols article: Gallagher,
2012), and dialysis (see Current Protocols article: Phillips & Signs, 20005)
1. Perform in silico design using ApE, SnapGene, or Vector NTI software of a synthetic
DNA encoding ADDomer in the BioBrick format with functionalized insertion loci
for facile and rapid custom DNA insertion. Make sure to maintain, on the DNA level,
the exact restriction enzyme recognition sequences flanking the epitope insertion
sites (Fig. 6), thus adhering to the BioBrick design. Importantly, verify.
2. Flank the insertion loci with the unique restriction sites (Fig. 6) that were removed
from anywhere else in the Ad3 penton base encoding gene.
This makes sure that the BioBrick format is adhered to.
3. For the BioBrick design, paste restriction sites flanking the insertion loci in regions
devoid of any secondary structure elements (check for secondary structure−devoid
region in the structure of penton base protein in PyMOL), maintaining the structural
integrity of the penton base protein.
4. After synthesis of the gene encoding ADDomer and codon optimization for recombi-
nant expression in insect cells (offered free of charge nowadays by all DNA synthesis
companies: e.g., Genscript, Twist, ThermoFisher, etc.), insert the designed synthetic
DNA into pACEBac1 plasmids by digesting the plasmid with BamHI and HindIII
restriction enzymes and carrying out ligation according to standard protocols [see,
e.g., New England Biolabs (NEB) catalog at https:// international.neb.com/ ] to yield
pACEBac-ADDomer.
5. Integrate pACEBac-ADDomer into the EMBacY baculoviral genome via Tn7 trans-
position (see Current Protocols article Bieniossek et al., 2012, Basic Protocol 4).
Tn7 transposition happens via Tn7 L and Tn7 R present on the transfer plasmid into
the attTn7 site present in the EMBacY baculoviral genome. The primary sequence of the
encoded ADDomer is provided (Fig. 7).
6. Based on established protocols, transfect to generate live virions and ADDomer ex-
pressed in Hi5 insect cells (Bieniossek et al., 2008).
Hi5 insect cells should be pre-adapted to flask and maintained every day to keep the cell
density at optimal growth level, 0.5-1 million cell per ml.
a. Generate V0 and V1 virus as described in step 7 of Basic Protocol 1 and step 4 of
Basic Protocol 2, respectively.
b. Define optimal volume of V1 virus needed for infection of insect cells by infecting
cells with different volumes of it, and then use that volume to infect insect cells
to make baculovirus-infected insect cells (BIICs).
c. For this, collect 200 ml infected at 1 million cell per ml concentration cells on
day of proliferation arrest by centrifuging 10 min at 400-600 × g, 26°C.
d. Resuspend in a filter-sterilized mix of 18 ml Sf900 medium, 0.2 g BSA, and 2
ml of DMSO. Prepare 1-ml aliquots in cryovials, place at –20°C for 1 hr, then at
–80°C for 24-48 hr, and then finally store in liquid nitrogen.
e. Use BIICs to do large-scale expression in Hi5 insect cells by adding 1 alliquot
of BIIC to 1 L of insect cells at 1 million cells per ml concentration. Harvest the
cells 48-72 hr post infection by centrifuging 10 min at 1000 × g, 4°C, for 10 min
and then storing the pellet at −80°C after flash freezing in liquid nitrogen.
7. Resuspend flash-frozen insect cell pellets which expressed ADDomer in hypotonic
lysis buffer and lyse three times via freezing in liquid nitrogen and thawing on ice.
8. Prepare a continuous sucrose gradient by mixing 15% and 40% (w/v) sucrose solu-
tions made in PBS with Gradient Master 107. Clarify lysate from debris via centrifu-
gation for 30 min at 6000 × g, 4°C, prior to subjecting the cleared supernatant to a Sari-Ak et al.
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Figure 7 ADDomer© VLP scaffold sequence. Three parts in the protomer region which are evolu-
tionarily nonconserved engineered with BioBrick format into exchangeable cassettes. One cassette
(colored in red) is placed within the VL region, while two additional cassettes, RGD1 (colored in
light blue) and RGD2 (colored in dark blue), are located within the loop including a functional RGD
tripeptide sequence. Amino acid residues encoded by restriction enzymatic sites in BioBrick design
are indicated (colored in yellow and boxed). The RGD tripeptide sequence is highlighted (colored
in green).
continuous sucrose gradient (15% to 40%) centrifugation (Fender, Ruigrok, Gout,
Buffet, & Chroboczek, 1997). Load the lysate on the gradient and ultracentrifuge
for 18 hr in Beckman SW 41 rotor at 287,472 × g, 4°C.
9. Combine ADDomer-containing fractions as identified by SDS-PAGE analysis of the
fractions (see Current Protocols article: Gallagher, 2012), which migrate in the gra-
dient at about 30% to 40% sucrose. Dialyze (see Current Protocols article: Phillips
& Signs, 2005) the combined fractions against purification buffer using a 6-8 kDa
MWCO dialysis at 4°C overnight.
10. Further purify ADDomer by ion-exchange chromatography via a High Q column
(Bio-Rad) with 50 mM NaCl purification buffer and applying a linear salt gra-
dient from 50 to 500 mM NaCl purification buffer. Equilibrate the column prior





11. Identify fractions containing purified ADDomer by tracking absorbance at 280 nm
and analyzing fractions by SDS-PAGE (Gallagher, 2012) These fractions elute be-
tween 330 and 400 mM NaCl, which can be conveniently traced by monitoring con-
ductance. Pool fractions comprising ADDomer and store at ambient temperature or
frozen (−80°C).
12. Purify additional ADDomer variants of choice designed in step 1 according to the
same protocol (Fig. 6). Choose the number of ADDomer variants you wish to purify
depending on the availability of the purification equipment in your laboratory and
the level of automation.
BASIC
PROTOCOL 5
ADDomer© CANDIDATE VACCINES AGAINST INFECTIOUS DISEASES
Infectious diseases continue to constitute major global challenges, forcefully evidenced
most recently by the SARS 2 coronavirus outbreak that caused the COVID-19 pan-
demic, wreaking havoc world-wide. Vaccination is uniquely suited to overcome these se-
rious threats. Pre-COVID-19, Zika and Chikungunya virus infectious diseases, which are
transmitted by mosquitoes, were causing alarm. Originally confined to sub-Saharan
Africa, these diseases are increasingly spreading to the Northern Hemisphere,
accelerated by deforestation and global warming. In the Chikungunya virus, the E2EP3
linear peptide has been identified as the major neutralizing epitope, with specific anti-
bodies present in the majority of patients (Kam et al., 2012). The E2EP3 neutralizing
epitope is located at the N terminus of the viral E2 glycoprotein, including the first 18
amino acids starting from N-terminal serine (Fig. 7 and Table 2). pACEBac-ADDomer is
used as a backbone in this protocol for inserting DNA encoding for this E2EP3 epitope.
The steps described in Basic Protocol 4 for purification of the vaccine candidate are used
in this protocol.
Materials
pACEBac-ADDomer (Basic Protocol 4, step 4)
E2EP3 neutralizing epitope peptide (see Fig. 7 and Table 2)
DH10EMBacY cells (Geneva Biotech SARL, Switzerland)
Hi5 insect cells
Phosphate-buffered saline (PBS)
EDTA-free complete protease inhibitor (Roche, Switzerland)
High Q column (Bio-Rad)
1. Insert E2EP3 into ADDomer© to create ADDomer-tevCHIK VLP vaccine candidate
to combat Chikungunya infectious disease (Basic Protocol 4 steps 1-4).
2. Apply steps 5-12 of Basic Protocol 4 here to purify the Chikungunya vaccine can-
didate, by using the plasmid generated in step 1 of Basic Protocol 5 instead of
pACEBac-ADDomer.
3. At the N-terminus of E2EP3 in ADDomer©, a site for a highly specific protease [to-
bacco etch virus (TEV) NIa] is included preceding the epitope. Thus, upon cleavage,
generate a native-like conformation comprising an exposed N-terminal serine.
Of note, negative-stain EM analysis confirmed that the ADDomer dodecahedron stayed
intact in spite of 60-fold cleavage by TEV (Fig. 8; Vragniau et al., 2019).
4. Our approach is validated with immunization experiments. Sera of mice injected
with uncut ADDomer-tevCHIK did not yield E2EP3-specific immunoglobulin titers
when assayed against synthetic E2EP3 peptides in an enzyme-linked immunosorbent
assay (ELISA; Vragniau et al., 2019). In contrast, TEV NIa quantitatively cleaved




Figure 8 Native-like peptide epitope presentation on ADDomer-tevCHIK. Chikungunya envelope
protein E2 consisting of three domains is shown (A, B, and C). E2EP3 (comprises the N-terminus
of E2 with the amino acid sequence NH2-STDKDNFNVYKATRPYLAH). This E2E3P peptide, the
major neutralizing epitope in the Chikungunya virus, is presented in an exposed native-like con-
formation in ADDomer-tevCHIK, with native-like meaning that the N-terminal serine residue of the
epitope is accessible exactly as is the case in the Chikungunya viral envelope protein containing
the major neutralizing epitope E2EP3. The N-terminus was liberated by TEV protease cleavage at
a specific site as indicated.
immunoglobulin G (IgG) response in ELISA when injected into mice, in agree-
ment with the immune reaction that is observed in patients after Chikungunya viral
infection.
5. An unrelated nanoparticle scaffold made of polylactic acid fused to a similar amount
of E2EP3 peptide epitopes did not elicit a comparable immune response, indicating
that the ADDomer© scaffold itself may have an adjuvating effect.
REAGENTS AND SOLUTIONS
Hypotonic lysis buffer
Prepare 0.33× phosphate-buffered saline (PBS, Thermo Fisher Scientific, cat. no.
10010023 supplemented with EDTA-free cOmplete protease inhibitor (Roche, cat.
no. 11873 580001; 1 tablet per 50 ml).
Purification buffer gradient solutions
Prepare 10 mM HEPES (pH 7.4) containing 50 mM NaCl and 500 mM NaCl. Fil-
ter sterilize and store at 4°C up to 1-2 months or longer. Just before purification,
supplement with one EDTA-free cOmplete protease inhibitor per 50 ml.
COMMENTARY
Background Information
Virus-like particles (VLPs) are large pro-
tein assemblies that self-assemble into struc-
tures mimicking naturally occurring viruses in
shape and size. VLPs can induce strong im-
mune responses but are not infectious, as they
do not contain viral genetic material. VLPs
are cornerstones of vaccine development. The
first VLP-based vaccine was the HBV vaccine
HEPTAVAX-B by Merck in 1981 (Zhao, Li,
Yu, Xia, & Modis, 2013). Other examples in-
clude VLP-based HPV vaccines such as Gar-
dasil1 (Merck) and Cervarix1 (GlaxoSmithK-
line), which are produced in yeast and insect
cells, respectively (Rodriguez-Limas, Sekar,
& Tyo, 2013).
There are important advantages when us-
ing VLPs in vaccine development and de-
ploying them against emerging viruses. VLPs
are considered safe due to their lack of ge-
netic material, setting them apart from heat-
inactivated or attenuated live virions, which
have intact genomes and could possibly re-
vert again to replicating pathogens. Thus,Sari-Ak et al.
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VLPs provide a safe(r) research and applica-
tion framework. VLPs may present major anti-
gens and elicit strong immune responses, as
they also contain repetitively arranged surface
proteins with viral epitopes, similar to native
viruses. VLPs were shown to induce strong
B cell responses (Roldaõ, Mellado, Castilho,
Carrondo, & Alves, 2010), but can also ac-
tivate the cellular response by internalization
in antigen-presenting cells that activate CD4+
and CD8+ T cells (Chackerian, Lenz, Lowy,
& Schiller, 2002; Cox et al., 2014; Wagner,
Deml, Schirmbeck, Reimann, & Wolf, 1994).
A major advantage is that VLPs can often
be produced recombinantly, resulting in cost-
effective vaccines that are particularly benefi-
cial for deployment in low-income countries
(Roldaõ et al., 2010).
A range of recombinant expression plat-
forms are successfully used for VLP produc-
tion, each with their own merits. These include
bacteria (E. coli), yeast, insect cells, mam-
malian cells, plant expression systems, and
more recently also in vitro cell-free systems.
E. coli has been used to produce several com-
mercial VLP vaccines, for example against
hepatitis (Hecolin1, Xiamen Innovax Biotech
Co. Ltd.). Even though bacterial expression
is cheaper and easier to handle, it lacks post-
translational modifications and sophisticated
folding machinery that may be required
for more complex VLPs. Yeast was used
for the HBV vaccine Engerix-B R© (Glaxo-
SmithKline) and the HPV vaccine Gardasil R©.
Alternatively, baculovirus/insect cell and
mammalian systems that afford authentic
post-translational modifications including
glycosylation and a sophisticated folding
machinery can be more suitable for producing
complex VLPs at high levels (Rodriguez-
Limas et al., 2013). Examples include the
HPV vaccine Cervix R© and the HBV vaccine
GenHevac B R© (Pasteur-Meŕieux Aventis),
which were produced using these systems.
The baculovirus insect cell system has the
added advantage of operating in a regular
lab safety level environment (BSL-1) due to
its narrow host range (insect cells) largely
eliminating any biological hazard for the
user.
VLPs such as the influenza VLPs de-
scribed here may comprise several antigenic
components (e.g., HA, NA, M2) in addi-
tion to the component forming the particle
(M1). The MultiBac baculovirus insect cell
expression system is particularly suited for co-
expressing multiple genes from a single bac-
ulovirus (Berger et al., 2004; Fitzgerald et al.,
2006; Fitzgerald et al., 2007). This enables
not only the co-expression of multiple anti-
genic components to produce potentially su-
perior VLPs that mimic live viruses, but also
enables provision of additional factors, for ex-
ample specific chaperones to facilitate produc-
tion of the product of choice.
The MultiBac baculoviral genome is propa-
gated as a single-copy bacterial artificial chro-
mosome in specialized E. coli strains (Luckow
& Summers, 1988, Berger et al., 2004; Fitzger-
ald et al., 2006), which greatly simplifies in-
tegration of genes encoding the components
of VLPs. The very strong polyhedrin (polh)
and p10 late viral promoters (Belyaev & Roy,
1993) used for driving recombinant expres-
sion often result in excellent expression levels
on the order of magnitude observed here for
ADDomer©. Nonetheless, if needed, any other
viral or cellular promoter can be utilized by ad-
justing the modular transfer plasmids (Table 1;
Fitzgerald et al., 2006).
Virus performance and sample production
can be easily monitored by co-expressing flu-
orescent proteins as reporters (e.g., mCherry
as in this protocol). These reporter genes are
easily co-integrated into the MultiBac bac-
uloviral genome, in addition to the genes en-
coding the components of a VLP of choice.
Monitoring the reporter boosts reproducibility
and enables the development of customized,
controlled, and standardized operating pro-
tocols, which are essential prerequisites for





The production of MultiBac-based VLP ar-
ray includes the step for generation of modu-
lar expression cassettes, and specific restric-
tion enzymes are part of the protocol (e.g.,
PmeI, SpeI, AvrII, BstZ17I and/or NruI). Ide-
ally, these are eliminated from the ensemble of
genes relevant for the production of the VLP
of choice. This is best accomplished by order-
ing the synthetic genes with this requirement
in mind.
In vitro Cre recombination of Acceptor and
Donor derivatives
It may be planned to utilize in vitro Cre re-
combination (Fitzgerald et al., 2006) to fuse
gene expression cassettes for multicomponent




the MultiBac system (Table 1) has a unique re-
sistance marker. The resistance marker com-
binations resulting from Cre fusion enable
selection of desired fusions following transfor-
mation of the Cre-fusion reactions into pir−
strains (e.g., TOP10 or DH5α). Plasmids re-
sulting from incomplete fusion will then be
eliminated based on the conditional R6Kγ ori-
gin of replication, which is not recognized in
pir− cells. For example, multigene plasmid
assembly can be performed in a single reac-
tion with, e.g., two Donor derivatives (with
different resistance markers) and one Accep-
tor, and the fusions can be monitored on agar
plates including the three respective antibi-
otics. We have found this method often prefer-
able and more versatile compared to classical
or ligation-independent cloning methods to as-
semble multiexpression constructs.
Integration of multiple copies of same
Donor
It can, however, occur (rarely) that several
copies of a Donor are combined with one
Acceptor during the in vitro Cre-fusion step.
This can be verified by using restriction map-
ping based on predictions from the software
Cre-ACEMBLER, which we developed and
which is available online (Nie et al., 2016;
Sari et al., 2016). Often, the resulting multiex-
pression construct can nonetheless be used for
MultiBac-based expression, sometimes even
in a beneficial manner, as multiple insertion
of the same gene may result in increased
expression.
Using both loxP and Tn7 sites for
integration into MultiBac bacmid
When one wants to use both the loxP and
the Tn7 sites of the MultiBac baculoviral
genome for integration, it is recommended to
first occupy the loxP site by transforming the
corresponding Donor into DH10MultiBacCre
cells. This was the procedure applied here in
VLP-factory© for providing the genes encod-
ing H1N1 M1 and mCherry. Then, a blue pos-
itive clone comprising the composite bacmid
is picked in the blue/white screening for fur-
ther processing, and competent cells prepared.
In the next step, Acceptor derivatives com-
prising gene(s) of choice (here HA wild-type
and ISD mutants) are transformed into these
competent cells for insertion of Acceptor
derivatives, or Acceptor-Donor fusions, into
the Tn7 site (Fig. 1). Tetracycline should al-
ways be present when competent cells are pre-
pared, to maintain the Tn7 transposition fac-
tors encoded by a tet-resistant helper plasmid.
Transfection and cell proliferation
Occasionally, when following the standard
MultiBac protocol (Bieniossek et al., 2008;
Fitzgerald et al., 2006), the initial V0 and V1
viruses may have low titers, which may hap-
pen to new or inexperienced users of the sys-
tem. In this case, cell division initially can re-
quire a longer time before proliferation arrest,
indicating wholesale infection of all cells in
the culture. This issue can be overcome by
repeating the experiment, providing a larger
virus volume used for infection. If no prolifer-
ation arrest is observed even with more virus
added, it is recommended to repeat the initial
transfections. Conversely, immediate cell pro-
liferation arrest can be observed if the virus
titers are too high. Then, the cell culture should
not be used for virus production, as defective
virus can accumulate and give diminishing tar-
get protein expression. In this case, we sug-
gest repeating the experiment with less virus
added.
Protein production levels
Insect cells may age over time, and the pro-
tein expression level can be affected by cell
aging. To forestall this, it is recommended to
change to a fresh cell culture thawed from
frozen stocks every 8-12 weeks. Importantly,
the recommended shaker flask volumes should
be followed closely to ascertain proper aera-
tion (Fitzgerald et al., 2006). For cell adapta-
tion from frozen stock or monolayer to flasks,
it is advised to let them divide at least once be-
fore infecting them with the virus. If no target
protein expression is observed, infection can
be repeated, varying virus volumes at the same
time. A new initial transfection with the same
expression construct should also be started, to
avoid losing time given that the protocols for
insect cell expression are measured in days
(rather than hours as for expression in E. coli).
Understanding Results
The MultiBac expression system we use
here has proven its aptitude for success-
ful production of complex protein biologics
including VLPs. Our MultiBac-based VLP-
factoryTM can be used to produce many dif-
ferent enveloped VLPs in addition to the in-
fluenza VLPs described here. The versatility
of the approach combined with the high yields
obtained enable rapid testing of many vari-
ants of a given VLP, as exemplified here for
immune-suppressive domain mutations in HA
glycoproteins of the influenza virus, helping to
identify suitable, ideally hyper-immunogenic




Figure 9 Genetically encoded multiepitope display by ADDomer©. Coomassie-stained SDS-
PAGE of ADDomer© VLPs is shown displaying a range of epitope arrangements (see Table 2).
CHIMP, chimpanzee; OVA, melanoma model epitope; CHICK, Chikungunya major neutralizing epi-
tope; tev, Tobacco Etch Virus NIa proteolytic site; M1, M2 are molecular weight markers (sizes in
kDa). The variability of the migration pattern of the ADDomer band reflects the different sizes of
the constructs.
similar vein, VLP-factoryTM or a correspond-
ing MultiBac-based system may be useful
to develop next-generation vaccines against
SARS 2 coronavirus, the causative agent of the
COVID-19 pandemic.
We also present here a non-enveloped
type of synthetic VLP, the ADDomer©. The
plug-and-play setup enables simple insertion
of entire libraries of immunogenic epitopes, in
multiple copies, from a wide range of human
and livestock viral pathogens. ADDomer©
has a remarkable capacity to accommodate
very large multiepitope insertions in the loci
that we engineered (Fig. 9; Table 2). For
example, we successfully inserted multiple
copies of immunogenic epitopes arranged in a
string, derived from Gumboro virus. Gumboro
causes infectious bursal disease which affects
young chickens, turkeys, and ducks, causing
considerable economic damage especially
in developing countries. Both VL and RGD
loops accommodated the epitope strings with-
out detrimental effect on dodecahedron in-
tegrity. In a different experiment, we inserted
an artificial epitope comprising more 200
amino acid residues in the RGD loop, result-
ing in fully functional particles, demonstrating
that long sequences, maybe even represent-
ing structured domains, can be efficiently
displayed at high density on the ADDomer©.
Time Considerations
The time needed for the cloning strategy
and then cloning the genes of interest into
multigene transfer vectors can vary based on
the number of subunits present in the VLPs of
choice, the strategy chosen, and the experience
of the researcher. It can take several weeks.
This time can be considerably shortened by
ordering synthetic DNAs now offered at very
competitive prices.
Preparation of DH10VLP-factoryTM
aliquots requires 2 to 3 days, and then trans-
formation of the transfer plasmid into one
of the DH10VLP-factoryTM aliquots and
composite bacmid isolation will take another
2 to 3 days.
Insect cell cultures should be monitored
every 24 hr for their density and prolifer-
ation, which is probably the most tvime-
consuming part of this protocol. Most of the
manipulations of the cell cultures must be im-
plemented in a sterile hood. After initial trans-
fection, about 60 hr later, V0 virus can be
harvested. Afterwards, virus is amplified and
VLPs produced. The time needed for all cells
to be infected and reach the point of prolifer-
ation arrest so that V1 virus can be collected
is 48-60 hr. After 48-60 hr, more than 95%
of cells are infected with the VLP-producing
baculovirus. Cell harvesting time also need
to be taken into consideration, as cell viabil-
ity usually starts dropping 72 hr after prolif-
eration arrest. Also, for the majority of pro-
teins, there is an expression plateau between
72 and 84 hr post infection. As we described
here for VLP-factoryTM production of flu VLP
arrays, the logistics for each round encom-
passed production in batches of 25 different
VLPs, each in 50 ml of cell culture in a 250-ml
Erlenmeyer flasks. For each individual VLP
produced, V0 and V1 collection should be
done separately to forestall cross contamina-
tion. This can take several hours/days to com-





Analyzing the expression of VLPs typically
requires SDS-PAGE, given the usual high ex-
pression of the target proteins. Preparing and
running SDS-PAGE and staining of the gel
with a protein dye will require on the order of
3-4 hr. Typical yields per liter of culture vary
between different VLP constructs, but we have
obtained up to 500 mg/L.
Analysis of the VLPs for functionality, in
particular as candidate vaccines, will strongly
depend on the animal models required and the
disease indications, and will vary from case to
case.
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